治疗药物-话题@MedSci

#治疗药物#

300篇内容 | 2609人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1921824, encodeId=8adf19218247b, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=FDA干眼病治疗药物开发指南（草案） 2020, objectType=article, longId=208536, objectId=53572085368d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53572085368d, replyNumber=0, likeNumber=46, createdTime=2021-07-25, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53572085368d, moduleTitle=FDA干眼病治疗药物开发指南（草案） 2020, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53572085368d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921813, encodeId=9a7e1921813be, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, objectType=article, longId=204053, objectId=0bbe204053d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bbe204053d5, replyNumber=0, likeNumber=78, createdTime=2021-04-28, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bbe204053d5, moduleTitle=FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bbe204053d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921841, encodeId=9347192184126, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=全是干货！27种STEMI治疗药物使用要点大集合！, objectType=article, longId=215233, objectId=d74d21523335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d74d21523335, replyNumber=0, likeNumber=0, createdTime=2022-07-15, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d74d21523335, moduleTitle=全是干货！27种STEMI治疗药物使用要点大集合！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d74d21523335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921823, encodeId=e0cc1921823e2, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=过敏性疾病取得里程碑进展，全球蒿属花粉舌下免疫治疗药物上市, objectType=article, longId=209364, objectId=17682093649c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17682093649c, replyNumber=0, likeNumber=88, createdTime=2022-02-10, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17682093649c, moduleTitle=过敏性疾病取得里程碑进展，全球蒿属花粉舌下免疫治疗药物上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17682093649c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921836, encodeId=49cc19218368f, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物, objectType=article, longId=213534, objectId=bbe3213534a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbe3213534a2, replyNumber=0, likeNumber=63, createdTime=2021-08-15, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbe3213534a2, moduleTitle=Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbe3213534a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921811, encodeId=cfaa1921811f0, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=琅铧医药获发作性睡病治疗药物Wakix(pitolisant) 中国**权益, objectType=article, longId=203242, objectId=a3a220324236, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3a220324236, replyNumber=0, likeNumber=133, createdTime=2021-03-23, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3a220324236, moduleTitle=琅铧医药获发作性睡病治疗药物Wakix(pitolisant) 中国**权益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3a220324236)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921822, encodeId=c8f219218222f, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=综述：靶向蛋白降解(PROTACs)癌症治疗药物机制、以及新近进展、国内相关研发公司, objectType=article, longId=209142, objectId=df2420914253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2420914253, replyNumber=0, likeNumber=67, createdTime=2022-02-27, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2420914253, moduleTitle=综述：靶向蛋白降解(PROTACs)癌症治疗药物机制、以及新近进展、国内相关研发公司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2420914253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921816, encodeId=e8a619218165c, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=埃博拉病毒治疗药物ansuvimab-zykl已获得FDA批准, objectType=article, longId=204985, objectId=cbfa20498514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbfa20498514, replyNumber=0, likeNumber=71, createdTime=2021-09-16, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbfa20498514, moduleTitle=埃博拉病毒治疗药物ansuvimab-zykl已获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbfa20498514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921831, encodeId=18eb192183124, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=JAMA：传统合成改善病情抗风湿药维持治疗药物剂量对复发风险的影响, objectType=article, longId=210945, objectId=ba132109453b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba132109453b, replyNumber=0, likeNumber=66, createdTime=2021-12-16, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba132109453b, moduleTitle=JAMA：传统合成改善病情抗风湿药维持治疗药物剂量对复发风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba132109453b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921819, encodeId=c1a419218196e, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, objectType=article, longId=207762, objectId=4aba20e76244, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4aba20e76244, replyNumber=0, likeNumber=93, createdTime=2021-10-29, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4aba20e76244, moduleTitle=葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4aba20e76244)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921833, encodeId=76841921833a1, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=Br J Cancer：安罗替尼（Anlotinib）：小细胞肺癌患者的三线或后续治疗药物, objectType=article, longId=211714, objectId=6de3211e1448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6de3211e1448, replyNumber=0, likeNumber=85, createdTime=2022-02-14, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6de3211e1448, moduleTitle=Br J Cancer：安罗替尼（Anlotinib）：小细胞肺癌患者的三线或后续治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6de3211e1448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921801, encodeId=dbce1921801ed, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=靶向TROP2治疗药物DS-1062是NSCLC和乳腺癌的新星？, objectType=article, longId=199024, objectId=524f199024ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524f199024ef, replyNumber=0, likeNumber=73, createdTime=2021-03-28, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524f199024ef, moduleTitle=靶向TROP2治疗药物DS-1062是NSCLC和乳腺癌的新星？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524f199024ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921825, encodeId=2b23192182567, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle= 基石药业再传喜讯！精准治疗药物泰吉华®获批上市，中国胃肠道间质瘤患者迎来新疗法, objectType=article, longId=209513, objectId=e01c2095131c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01c2095131c, replyNumber=0, likeNumber=82, createdTime=2022-03-20, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01c2095131c, moduleTitle= 基石药业再传喜讯！精准治疗药物泰吉华®获批上市，中国胃肠道间质瘤患者迎来新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e01c2095131c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921809, encodeId=d6c419218099c, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, objectType=article, longId=202131, objectId=d48b202131f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d48b202131f6, replyNumber=0, likeNumber=30, createdTime=2021-02-27, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d48b202131f6, moduleTitle=再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d48b202131f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921821, encodeId=5bb11921821b9, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=JAMA：提高预防性抗凝治疗药物剂量对ICU新冠肺炎患者预后的影响, objectType=article, longId=208860, objectId=35ad20886078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35ad20886078, replyNumber=0, likeNumber=102, createdTime=2021-06-19, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35ad20886078, moduleTitle=JAMA：提高预防性抗凝治疗药物剂量对ICU新冠肺炎患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35ad20886078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921827, encodeId=3019192182ec4, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=三阴性乳腺癌何时才能产出里程碑式治疗药物？, objectType=article, longId=209768, objectId=27d1209e681f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27d1209e681f, replyNumber=0, likeNumber=73, createdTime=2021-08-03, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27d1209e681f, moduleTitle=三阴性乳腺癌何时才能产出里程碑式治疗药物？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27d1209e681f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921798, encodeId=32dc1921e989e, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=吉利德在发达国家将COVID-19治疗药物瑞德西韦的价格定为每瓶390美元, objectType=article, longId=196780, objectId=75be196e800f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75be196e800f, replyNumber=0, likeNumber=58, createdTime=2021-01-07, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75be196e800f, moduleTitle=吉利德在发达国家将COVID-19治疗药物瑞德西韦的价格定为每瓶390美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75be196e800f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921815, encodeId=b3b4192181515, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=五类新型肿瘤免疫治疗药物，加强版PD-1药物即将到来, objectType=article, longId=204274, objectId=06f22042e4c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06f22042e4c0, replyNumber=0, likeNumber=77, createdTime=2020-12-20, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06f22042e4c0, moduleTitle=五类新型肿瘤免疫治疗药物，加强版PD-1药物即将到来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06f22042e4c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921795, encodeId=51031921e9546, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=泊马度胺获FDA批准，成为20多年来艾滋病相关卡波西肉瘤的治疗药物, objectType=article, longId=194313, objectId=523f194313d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=523f194313d8, replyNumber=0, likeNumber=58, createdTime=2020-09-26, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=523f194313d8, moduleTitle=泊马度胺获FDA批准，成为20多年来艾滋病相关卡波西肉瘤的治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=523f194313d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1921806, encodeId=9e60192180638, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, objectTitle=CSCO 2020丨CDE高级审评员夏琳：肿瘤免疫治疗药物的临床研发和审评考虑, objectType=article, longId=201052, objectId=27f8201052b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27f8201052b6, replyNumber=0, likeNumber=25, createdTime=2021-09-05, rootId=0, userName=周虎, userId=c9d3459, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27f8201052b6, moduleTitle=CSCO 2020丨CDE高级审评员夏琳：肿瘤免疫治疗药物的临床研发和审评考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27f8201052b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

治疗药物

2020-05-29

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

FDA干眼病治疗药物开发指南（草案） 2020

2021-07-25

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

FDA延长法布雷病治疗药物长效α-半乳糖苷酶A产品pegunigalsidase alfa审查周期

2021-04-28

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

全是干货！27种STEMI治疗药物使用要点大集合！

2022-07-15

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

过敏性疾病取得里程碑进展，全球蒿属花粉舌下免疫治疗药物上市

2022-02-10

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Br J Cancer：Migrastatic：转移性黑色素瘤的潜在抗转移治疗药物

2021-08-15

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

琅铧医药获发作性睡病治疗药物Wakix(pitolisant) 中国**权益

2021-03-23

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

综述：靶向蛋白降解(PROTACs)癌症治疗药物机制、以及新近进展、国内相关研发公司

2022-02-27

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

埃博拉病毒治疗药物ansuvimab-zykl已获得FDA批准

2021-09-16

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

JAMA：传统合成改善病情抗风湿药维持治疗药物剂量对复发风险的影响

2021-12-16

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

葛兰素史克中枢神经系统治疗药物利必通获批新适应症，为双相情感障碍患者带来一线用药新选择

2021-10-29

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

Br J Cancer：安罗替尼（Anlotinib）：小细胞肺癌患者的三线或后续治疗药物

2022-02-14

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

靶向TROP2治疗药物DS-1062是NSCLC和乳腺癌的新星？

2021-03-28

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

基石药业再传喜讯！精准治疗药物泰吉华®获批上市，中国胃肠道间质瘤患者迎来新疗法

2022-03-20

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

再生元的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物

2021-02-27

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

JAMA：提高预防性抗凝治疗药物剂量对ICU新冠肺炎患者预后的影响

2021-06-19

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

三阴性乳腺癌何时才能产出里程碑式治疗药物？

2021-08-03

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

吉利德在发达国家将COVID-19治疗药物瑞德西韦的价格定为每瓶390美元

2021-01-07

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

五类新型肿瘤免疫治疗药物，加强版PD-1药物即将到来

2020-12-20

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

泊马度胺获FDA批准，成为20多年来艾滋病相关卡波西肉瘤的治疗药物

2020-09-26

周虎 (审核中...)

前往app查看评论内容

#治疗药物#

CSCO 2020丨CDE高级审评员夏琳：肿瘤免疫治疗药物的临床研发和审评考虑

2021-09-05

科室
- - 订阅+
  - 更多科室
工具
服务